查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1721446

聚乙二醇化蛋白质市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

PEGylated Proteins Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球聚乙二醇化蛋白质市场价值为 18 亿美元，预计到 2034 年将以 10.9% 的复合年增长率成长，达到 51 亿美元。这一显着的成长趋势反映了蛋白质疗法在现代医学中的应用日益广泛。随着生物製剂和生物相似药在全球製药领域稳步发展，聚乙二醇化技术的角色变得越来越不可或缺。此过程涉及以聚乙二醇 (PEG) 对蛋白质或药物进行化学修饰，增强其稳定性、溶解度和半衰期。这些优点使得聚乙二醇化成为药物传递的重要工具，特别是对于单株抗体和重组蛋白等复杂生物製剂。

聚乙二醇化蛋白质市场 - IMG1

随着针对性治疗的研究力度不断加大，聚乙二醇化製剂因其改善的药物动力学和降低的免疫原性而成为首选。政府对生物製剂开发的支持不断增加，加上蛋白质疗法临床试验数量的增加，继续推动该领域的创新。癌症、自体免疫疾病和糖尿病等慢性和危及生命的疾病发生率不断上升，大大增加了对更安全、长效治疗方案的需求，进一步加强了市场扩张。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 18亿美元
预测值 51亿美元
复合年增长率 10.9%

市场大致分为消费品和服务。随着对专用 PEG 衍生物的需求不断增长，预测期内消耗品领域预计将实现 10.9% 的稳定复合年增长率。这些衍生物对于增强聚乙二醇化生物製剂（如单株抗体和酵素）的性能至关重要。随着全球慢性病发病率的上升，对具有长期疗效的先进治疗方法的需求促使人们更加依赖优质 PEG 试剂和聚合物。对提供更好的患者依从性和治疗效率的药物传递系统的重视也促进了这一类别的成长。

根据蛋白质类型，聚乙二醇化蛋白质市场包括干扰素、集落刺激因子 (CSF)、促红血球生成素、抗体、重组因子 VIII 和其他蛋白质类别。预计 2025 年至 2034 年期间 CSF 领域的复合年增长率为 11%，这主要是由于贫血和白血病等血液病患疾病率的不断上升。脑脊髓液在支持化疗和其他强化治疗患者的骨髓恢復和增强免疫功能方面发挥关键作用。它们的应用也扩展到干细胞动员和慢性中性粒细胞减少症等新的治疗领域。

2024 年，美国聚乙二醇化蛋白质市场规模达到 7.352 亿美元，预计在慢性病高发病率和先进医疗基础设施的推动下，该市场将大幅成长。製药公司的高度集中和聚乙二醇化技术的持续创新正在帮助美国保持主导市场地位。

全球市场的关键参与者包括 Biopharma PEG Scientific、Merck KGaA、Celares、Abcam、Biomatrik、Enzon Pharmaceuticals、JenKem Technology、Aurigene Pharmaceutical Services、Quanta BioDesign、Thermo Fisher Scientific、Laysan Bio、Iris Biotech、Profacgen、Creative Corporation。这些公司正在透过研发投资、产品组合扩展、收购和合作策略来提高治疗效果和全球市场占有率。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 慢性病盛行率上升
      • 聚乙二醇化在药物传递的优势
      • 不断成长的生物製药和生技产业
      • 聚乙二醇化药物的采用率不断提高
    • 产业陷阱与挑战
      • 聚乙二醇化和蛋白质类药物成本高
      • 监管挑战和严格的审批流程
  • 成长潜力分析
  • 监管格局
  • 技术格局
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 策略仪表板

第五章：市场估计与预测：依产品类型，2021 - 2034 年

  • 主要趋势
  • 耗材
  • 服务

第六章：市场估计与预测：按蛋白质类型，2021 - 2034 年

  • 主要趋势
  • 集落刺激因子
  • 干扰素
  • 促红血球生成素
  • 重组Ⅷ因子
  • 抗体
  • 其他蛋白质类型

第七章：市场估计与预测：按应用，2021 - 2034 年

  • 主要趋势
  • 癌症治疗
  • 自体免疫疾病
  • 血液系统疾病
  • 肝炎
  • 慢性肾臟疾病
  • 胃肠道疾病
  • 其他应用

第八章：市场估计与预测：依最终用途，2021 - 2034 年

  • 主要趋势
  • 製药和生物技术公司
  • CRO 和 CMO
  • 学术和研究机构

第九章：市场估计与预测：按地区，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • Abcam
  • Aurigene Pharmaceutical Services
  • Biomatrik
  • Biopharma PEG Scientific
  • Celares
  • Creative PEGworks
  • Enzon Pharmaceuticals
  • Iris Biotech
  • JenKem Technology
  • Laysan Bio
  • Merck KGaA
  • NOF Corporation
  • Profacgen
  • Quanta BioDesign
  • Thermo Fisher Scientific
简介目录
Product Code: 13422

The Global Pegylated Proteins Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 10.9% to reach USD 5.1 billion by 2034. This notable growth trend reflects the expanding use of protein-based therapeutics in modern medicine. With biologics and biosimilars steadily gaining traction in the global pharmaceutical space, the role of PEGylation technology is becoming increasingly indispensable. This process involves the chemical modification of proteins or drugs with polyethylene glycol (PEG), enhancing their stability, solubility, and half-life. These benefits make PEGylation an essential tool in drug delivery, especially for complex biologics like monoclonal antibodies and recombinant proteins.

PEGylated Proteins Market - IMG1

As research efforts intensify to develop targeted therapies, PEGylated formulations are emerging as a preferred choice due to their improved pharmacokinetics and reduced immunogenicity. Increasing government support for biologics development, combined with a higher volume of clinical trials in protein therapeutics, continues to push the boundaries of innovation within this sector. The growing incidence of chronic and life-threatening diseases, including cancer, autoimmune disorders, and diabetes, has significantly escalated the need for safer, long-acting treatment options-further reinforcing market expansion.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.8 Billion
Forecast Value$5.1 Billion
CAGR10.9%

The market is broadly segmented into consumables and services. The consumables segment is poised to witness a steady CAGR of 10.9% during the forecast period as the demand for specialized PEG derivatives rises. These derivatives are key to enhancing the performance of PEGylated biologics, such as monoclonal antibodies and enzymes. With chronic disease rates on the rise globally, the requirement for advanced therapeutics that offer prolonged efficacy is prompting greater reliance on premium-grade PEG reagents and polymers. The emphasis on drug delivery systems that provide better patient compliance and therapeutic efficiency is also bolstering growth within this category.

Based on protein type, the PEGylated proteins market includes interferons, colony-stimulating factors (CSF), erythropoietin, antibodies, recombinant factor VIII, and other protein categories. The CSF segment is projected to grow at a CAGR of 11% from 2025 to 2034, primarily due to the increasing prevalence of hematological disorders such as anemia and leukemia. CSFs play a critical role in supporting bone marrow recovery and enhancing immune function in patients undergoing chemotherapy and other intensive treatments. Their applications are also expanding into newer therapeutic areas like stem cell mobilization and chronic neutropenia.

The U.S. PEGylated Proteins Market reached USD 735.2 million in 2024 and is expected to grow substantially, driven by the high incidence of chronic illnesses and the presence of advanced healthcare infrastructure. A strong concentration of pharmaceutical companies and ongoing innovation in PEGylation technologies are helping the U.S. maintain a dominant market position.

Key players in the global market include Biopharma PEG Scientific, Merck KGaA, Celares, Abcam, Biomatrik, Enzon Pharmaceuticals, JenKem Technology, Aurigene Pharmaceutical Services, Quanta BioDesign, Thermo Fisher Scientific, Laysan Bio, Iris Biotech, Profacgen, Creative PEGworks, and NOF Corporation. These companies are advancing through R&D investments, portfolio expansion, acquisitions, and collaborative strategies to enhance therapeutic efficacy and global market presence.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic diseases
      • 3.2.1.2 Advantages of PEGylation in drug delivery
      • 3.2.1.3 Growing biopharmaceutical and biotechnology industry
      • 3.2.1.4 Increasing adoption of PEGylated drugs
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs of PEGylation and protein-based drugs
      • 3.2.2.2 Regulatory challenges and stringent approval processes
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Consumables
  • 5.3 Services

Chapter 6 Market Estimates and Forecast, By Protein Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Colony stimulating factors
  • 6.3 Interferons
  • 6.4 Erythropoietin
  • 6.5 Recombinant factor VIII
  • 6.6 Antibodies
  • 6.7 Other protein types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cancer treatment
  • 7.3 Autoimmune diseases
  • 7.4 Hematological disorders
  • 7.5 Hepatitis
  • 7.6 Chronic kidney diseases
  • 7.7 Gastrointestinal disorders
  • 7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Pharmaceutical and biotechnology companies
  • 8.3 CROs and CMOs
  • 8.4 Academic and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abcam
  • 10.2 Aurigene Pharmaceutical Services
  • 10.3 Biomatrik
  • 10.4 Biopharma PEG Scientific
  • 10.5 Celares
  • 10.6 Creative PEGworks
  • 10.7 Enzon Pharmaceuticals
  • 10.8 Iris Biotech
  • 10.9 JenKem Technology
  • 10.10 Laysan Bio
  • 10.11 Merck KGaA
  • 10.12 NOF Corporation
  • 10.13 Profacgen
  • 10.14 Quanta BioDesign
  • 10.15 Thermo Fisher Scientific